Nesiritide

For research use only. Not for therapeutic Use.

  • CAT Number: I000975
  • CAS Number: 124584-08-3
  • Molecular Formula: C143H244N50O42S4
  • Molecular Weight: 3464.05
  • Purity: ≥95%
Inquiry Now

Nesiritide(Cat No.:I000975)is a recombinant form of human B-type natriuretic peptide (BNP), a hormone that helps regulate fluid balance, blood pressure, and sodium levels. It is used primarily in the treatment of acute decompensated heart failure (ADHF) to reduce symptoms such as fluid retention and shortness of breath. Nesiritide works by dilating blood vessels, promoting natriuresis (excretion of sodium), and reducing the workload on the heart. Administered intravenously, it helps improve hemodynamics and alleviate congestion in heart failure patients, though its use has been controversial due to mixed outcomes in clinical studies.


Catalog Number I000975
CAS Number 124584-08-3
Synonyms

(1E,3S,4Z,6S,7Z,9S,10Z,12S,13Z,15S,16Z,18S)-18-((1H-imidazol-5-yl)methyl)-1-((4R,5E,8Z,10S,11Z,14Z,16S,17Z,19S,20Z,22S,23E,25S,26Z,28S,29Z,31S,32E,34S,35Z,37S,38E,40S,41Z,43S,44Z,47Z,49S,50Z,52R)-52-((Z)-((1Z,3S,4Z,6S,7Z,9S,10Z,12S,13Z,16Z,18S,19Z)-1

Molecular Formula C143H244N50O42S4
Purity ≥95%
Target Peptide and Derivatives
Solubility H2O
Storage Store at -20C
IUPAC Name 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
InChI InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)
InChIKey HPNRHPKXQZSDFX-UHFFFAOYSA-N
SMILES CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO
Reference

<p style=/line-height:25px/>
<br>[1]. Heublein DM et al. Immunoreactivity and guanosine 3/’,5/’-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007 May;49(5):1114-9.
<br>[2]. Tsuruda T et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002 Dec 13;91(12):1127-34.
<br>[3]. Wellard J et al. Natriuretic peptides, but not nitric oxide donors, elevate levels of cytosolic guanosine 3/’,5/’-cyclic monophosphate in ependymal cells ex vivo. Neurosci Lett. 2006 Jan 16;392(3):187-92.
</p>

Request a Quote